CureSHANK's mission is to improve the quality of life for individuals with Phelan-McDermid syndrome by fostering scientific and therapeutic advancements.
The CureSHANK Research-to-Cure Grant: Epilepsy (R2C Epilepsy) focuses on stimulating research in SHANK3-related epilepsy, following a roadmap developed on September 25, 2023, that identified key research priorities and gap areas. The grant encourages the development of translational research projects that could lead to improved understanding and treatment of SHANK3-related epilepsy, covering a range of interests from novel models for drug discovery and screening to clinical research characterizing SHANK3-related epilepsy. Priority is given to projects that aim to understand the natural history and development of epilepsy in Phelan-McDermid syndrome, identify genetic and brain structure differences influencing epilepsy in these patients, and improve models of epilepsy in this context. Funding is available for one or two years with a maximum of $125,000, dependent on progress made in the first year.
fugiat ex eiusmod laborum ex cupidatat ut aliqua eu velit velit consequat culpa proident adipisicing nisi eu mollit mollit excepteur eiusmod nisi aliqua laboris tempor est exercitation quis pariatur voluptate officia ipsum